News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
604,153 Results
Type
Article (49055)
Company Profile (117)
Press Release (554981)
Section
Business (166893)
Career Advice (2660)
Deals (28508)
Drug Delivery (104)
Drug Development (83857)
Employer Resources (157)
FDA (15241)
Job Trends (13401)
News (300111)
Policy (29402)
Tag
2024 BioCapital Digital (1)
2024 BioForest Digital (3)
2024 BioForest Standard (1)
2024 BioMidwest Digital (3)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (2)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (9)
2024 Biotech Beach Digital (5)
2024 Biotech Beach Standard (3)
2024 Genetown Standard (5)
2024 Lone Star Bio Digital (1)
2024 Pharm Country Digital (4)
2024 Pharm Country Standard (3)
2025 Lone Star Bio Digital (3)
2026 BioCapital Elite (1)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (1)
2026 Biotech Bay Elite (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (2)
2026 Pharm Country Elite (1)
2026 Pharm Country Standard (1)
Academia (2614)
Accelerated approval (1)
Adcomms (27)
Allergies (81)
Alliances (40957)
ALS (85)
Alzheimer's disease (1335)
Antibody-drug conjugate (ADC) (121)
Approvals (15207)
Artificial intelligence (219)
Autoimmune disease (15)
Automation (9)
Bankruptcy (243)
Best Places to Work (10550)
BIOSECURE Act (13)
Biosimilars (81)
Biotechnology (78)
Bladder cancer (54)
Brain cancer (27)
Breast cancer (247)
Cancer (1832)
Cardiovascular disease (152)
Career advice (2244)
Career pathing (31)
CAR-T (144)
Cell therapy (364)
Cervical cancer (16)
Clinical research (69174)
Collaboration (645)
Compensation (337)
Complete response letters (26)
COVID-19 (2661)
CRISPR (35)
C-suite (172)
Cystic fibrosis (94)
Data (1754)
Decentralized trials (2)
Denatured (18)
Depression (47)
Diabetes (232)
Diagnostics (5280)
Digital health (18)
Diversity (7)
Diversity, equity & inclusion (38)
Drug discovery (85)
Drug pricing (97)
Drug shortages (28)
Duchenne muscular dystrophy (71)
Earnings (68347)
Editorial (36)
Employer branding (18)
Employer resources (138)
Events (90084)
Executive appointments (542)
FDA (16250)
Featured Employer (34)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (6)
Funding (598)
Gene editing (88)
Generative AI (22)
Gene therapy (270)
GLP-1 (724)
Government (4517)
Grass and pollen (3)
Guidances (42)
Healthcare (17752)
Huntington's disease (23)
IgA nephropathy (22)
Immunology and inflammation (105)
Indications (23)
Infectious disease (2785)
Inflammatory bowel disease (131)
Inflation Reduction Act (9)
Influenza (43)
Intellectual property (60)
Interviews (472)
IPO (13466)
IRA (39)
Job creations (3280)
Job search strategy (1864)
Kidney cancer (10)
Labor market (18)
Layoffs (447)
Leadership (19)
Legal (6164)
Liver cancer (74)
Lung cancer (270)
Lymphoma (129)
Machine learning (2)
Management (58)
Manufacturing (221)
MASH (63)
Medical device (13710)
Medtech (13714)
Mergers & acquisitions (15446)
Metabolic disorders (633)
Multiple sclerosis (66)
NASH (23)
Neurodegenerative disease (83)
Neuropsychiatric disorders (27)
Neuroscience (1809)
NextGen: Class of 2025 (6111)
Non-profit (4339)
Northern California (1990)
Now hiring (19)
Obesity (348)
Opinion (236)
Ovarian cancer (63)
Pain (78)
Pancreatic cancer (71)
Parkinson's disease (125)
Partnered (14)
Patents (156)
Patient recruitment (86)
Peanut (48)
People (46966)
Pharmaceutical (35)
Pharmacy benefit managers (16)
Phase I (21467)
Phase II (30610)
Phase III (22975)
Pipeline (841)
Podcasts (79)
Policy (100)
Postmarket research (2342)
Preclinical (7347)
Press Release (51)
Prostate cancer (87)
Psychedelics (36)
Radiopharmaceuticals (234)
Rare diseases (357)
Real estate (4933)
Recruiting (65)
Regulatory (20624)
Reports (25)
Research institute (2295)
Resumes & cover letters (439)
Rett syndrome (3)
RNA editing (2)
RSV (39)
Schizophrenia (72)
Series A (105)
Series B (68)
Service/supplier (6)
Sickle cell disease (48)
Southern California (1747)
Special edition (13)
Sponsored (28)
Startups (3225)
State (1)
Stomach cancer (13)
Supply chain (49)
The Weekly (60)
United States (17800)
Vaccines (674)
Venture capitalists (35)
Webinars (9)
Weight loss (255)
Women's health (26)
Worklife (17)
Date
Today (49)
Last 7 days (539)
Last 30 days (2662)
Last 365 days (31031)
2025 (5944)
2024 (32144)
2023 (36385)
2022 (46711)
2021 (50804)
2020 (49144)
2019 (42938)
2018 (32855)
2017 (29710)
2016 (29095)
2015 (33512)
2014 (25984)
2013 (21690)
2012 (23187)
2011 (23748)
2010 (21741)
Location
Africa (789)
Alabama (41)
Alaska (5)
Arizona (169)
Arkansas (12)
Asia (37051)
Australia (6419)
California (4540)
Canada (1616)
China (412)
Colorado (223)
Connecticut (230)
Delaware (112)
Europe (80808)
Florida (709)
Georgia (179)
Idaho (54)
Illinois (450)
India (18)
Indiana (280)
Iowa (3)
Japan (126)
Kansas (86)
Kentucky (23)
Louisiana (7)
Maine (34)
Maryland (771)
Massachusetts (3323)
Michigan (165)
Minnesota (320)
Mississippi (2)
Missouri (69)
Montana (28)
Nebraska (22)
Nevada (48)
New Hampshire (64)
New Jersey (1382)
New Mexico (18)
New York (1336)
North Carolina (833)
North Dakota (6)
Northern California (1990)
Ohio (160)
Oklahoma (7)
Oregon (33)
Pennsylvania (1062)
Puerto Rico (8)
Rhode Island (23)
South America (1119)
South Carolina (15)
South Dakota (1)
Southern California (1747)
Tennessee (81)
Texas (682)
Utah (154)
Virginia (113)
Washington D.C. (49)
Washington State (396)
West Virginia (3)
Wisconsin (41)
604,153 Results for "phase one medical".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Evolus to Participate in Fireside Chats and One-on-One Meetings at Upcoming Investor Conferences
February 27, 2025
·
1 min read
Press Releases
Alterome Doses First Patient in Phase 1 Study of ALTA3263, a Novel Pan-KRAS Dual ON/OFF Inhibitor, in Advanced Solid Tumors
March 10, 2025
·
3 min read
Press Releases
ONWARD Medical Announces Publication of One-Year Study Showing Benefit of Sustained Access to ARC-EX Therapy
February 25, 2025
·
6 min read
Press Releases
Grace Therapeutics Announces Results From Pivotal Phase 3 STRIVE-ON Safety Trial of GTx-104 in aSAH
February 10, 2025
·
10 min read
Press Releases
Creative Medical Technology Reports Positive One-Year Results for AlloStem™ Type 2 Diabetes Program
February 12, 2025
·
3 min read
Depression
Neumora Shakes Up Phase III MDD Trials After January Miss
After failing to hit the primary endpoint in a Phase III trial, Neumora is remixing study parameters in two replicate trials, with data expected in the first half of 2026.
March 3, 2025
·
1 min read
·
Dan Samorodnitsky
Neuropsychiatric disorders
Biohaven Disappoints Again, This Time in Phase II/III Bipolar Mania Trial
Biohaven in recent months has reported a clinical stumble in spinal muscular atrophy, alongside a Phase I readout for its protein degrader candidate that investors found underwhelming.
March 4, 2025
·
2 min read
·
Tristan Manalac
Cancer
AstraZeneca Posts Positive Phase III Results for Oral Breast Cancer Drug
In the Phase III SERENA-6 trial, camizestrant—in combination with CDK-inhibitors—beat out current standard-of-care treatments in terms of progression-free survival, according to AstraZeneca.
February 26, 2025
·
1 min read
·
Dan Samorodnitsky
Drug Development
Positive One-Year Data from Phase 2 Study of Pegcetacoplan in Post-Transplant Recurrence of C3G and IC-MPGN Presented as Late-Breaker at ERA Congress
Apellis Pharmaceuticals, Inc. and Sobi® announced positive one-year results from the Phase 2 NOBLE study investigating systemic pegcetacoplan, a targeted C3 therapy, for the treatment of post-transplant recurrence of C3 glomerulopathy and primary immune complex membranoproliferative glomerulonephritis.
May 24, 2024
·
8 min read
Drug Development
Acasti Announces Achievement of 50% Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial
Acasti Pharma Inc. announced that the Company’s pivotal Phase 3 STRIVE-ON safety trial has exceeded the 50% enrollment milestone.
June 27, 2024
·
6 min read
1 of 60,416
Next
